Last reviewed · How we verify
NCT05163197: TPLAforPCa
Transperineal Laser Ablation Treatment (TPLA) for Prostate Cancer (PCa) Registry
trial testing Transperineal Laser Ablation of Prostate Cancer in Prostate Cancer in 200 participants. Currently enrolling.
1 October 2026
Quick facts
| Lead sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 October 2021 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 October 2027 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Transperineal Laser Ablation of Prostate Cancer
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full company profile →
Who can join
18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rationale: Transperineal laser ablation (TPLA) treatment for prostate cancer (PCa) is a minimal invasive focal therapy technique studied worldwide to determine its efficacy. In pilot studies it has shown to be a safe and feasible technique and it has potential to preserve continence and potency over current standard radical therapies. However, (long-term) treatment outcomes of TPLA for PCa remain largely unknown. The aim of this international retrospective registry is to collect and combine data on patients treated TPLA for PCa in order to provide data on safety, feasibility, functional and oncological outcomes. Objective: To assess safety and feasibility of TPLA for PCa, to assess functional and oncological outcomes of TPLA for PCa and to determine baseline patient characteristics in a multicentre cohort. Study design: This is an international, retrospective observational registry in which data is recorded of patients who have been treated with TPLA for PCa. Study population: Male patients treated with TPLA for PCa. Main study parameters/endpoints: The primary endpoint of this registry is oncological outcomes of TPLA for PCa. Secondary endpoints are safety, feasibility and functional outcomes of TPLA for PCa.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Focal ablation therapy presents promising results for selectively localized prostate cancer patients.
Feng D, Li D, Xiao Y, Wu R, et al · · 2023 · cited 22× · PMID 37691892 · DOI 10.21147/j.issn.1000-9604.2023.04.08 -
MRI-directed Micro-US-guided Transperineal Focal Laser Ablation for Localized Prostate Cancer: A 1-year Follow-up Study.
Cornud F, de Bie K, van Riel L, Lefèvre A, et al · · 2024 · cited 4× · PMID 39718499 · DOI 10.1148/radiol.233371 -
One-year Follow-up after US-guided Transperineal Focal Laser Ablation of Localized Prostate Cancer: Worldwide Registry Study.
de Bie KCC, Cornud FC, Walser EM, van Riel LAMJG, et al · · 2026 · PMID 42227864 · DOI 10.1148/radiol.251658
Verify or expand the search:
- PubMed search for NCT05163197
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials
Trials by the same sponsor.
- NCT07301021 — Velopharyngeal Insufficiency After Maxillomandibular Advancement Osteotomy in Obstructive Sleep Apnea Patients · not yet recruiting
- NCT07359482 — sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 · Phase 3 · not yet recruiting
- NCT07457957 — Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents · NA · not yet recruiting
- NCT06909045 — Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease · NA · recruiting
- NCT07316127 — Immunoadsorption in Autoimmune Long COVID · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05163197 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Last refreshed: 20 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05163197.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing